Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Phase Ⅱ Exploratory Clinical Study of Becotatug Vedotin Combined With Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy Plus Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal

NCT07800000 is registered in ClinicalTrials.gov with Wang Xin as lead sponsor.

NCT NCT07800000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07800000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Phase Ⅱ Exploratory Clinical Study of Becotatug Vedotin Combined With Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy Plus Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal
Lead sponsor
Wang Xin
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 20, 2026
Completion date
May 31, 2029
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the anal canal